Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
bimatoprost eye · 1 trial · 2 indications
Change from Baseline in macroscopic conjunctival hyperemia (or visible eye redness). Macroscopic conjunctival hyperemia is graded by the investigator who compares the patient's visual appearance of eye redness to standard photographs using a 5-point scale (Scale 0 to +3: none, trace, mild, moderate, severe). The peak change is calculated for each eye by subtracting the largest score across the hourly measurements at baseline from the largest score across the hourly measurements at month 1. A positive number severity grade change from baseline indicated an increase in redness.
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | bimatoprost eye drops |
| 2 | PLACEBO_COMPARATOR | placebo |
| Name | Type | Description |
|---|---|---|
| bimatoprost eye drops | DRUG | 1 drop in each eye daily for 1 month |
| placebo | DRUG | 1 drop in each eye daily for 1 month |
Inclusion Criteria: * Chronic glaucoma or ocular hypertension * IOP controlled on Xalatan Exclusion Criteria: * Uncontrolled medical conditions * Known hypersensitivity to study medications
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Glaukos Corp | GKOS | 6 | PHASE3 | Gen 2 Travoprost Intracameral, Timolol eye 0.5% |
| AbbVie, Inc. | ABBV | 2 | PHASE3 | Undisclosed |
| SpyGlass Pharma, Inc. | SGP | 4 | PHASE3 | Bimatoprost System, Timolol, 0.5% |
| Amneal Pharmaceuticals, Inc. Class A | AMRX | 2 | PHASE3 | Test- Bimatoprost 0.01%, Reference- LUMIGAN |
| Alcon AG | ALC | 5 | N/A | Undisclosed |
| Sight Sciences, Inc. | SGHT | 3 | N/A | Undisclosed |
Bimatoprost eye is a small molecule being developed by AbbVie Inc. (ABBV) for the treatment of glaucoma. It is currently in Phase 2 clinical development and is being studied in patients with glaucoma or ocular hypertension.
Bimatoprost eye is a small molecule in the ophthalmology therapeutic area. Its specific molecular target has not been disclosed in the available information, so its precise mechanism of action is not detailed here.
Bimatoprost eye is developed by AbbVie Inc., a biopharmaceutical company traded on the NYSE under the ticker symbol ABBV.
Bimatoprost eye is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 2 trial has been completed.
Bimatoprost eye has one completed Phase 2 trial, NCT00538304, titled "A Study of the Safety and Efficacy of Bimatoprost in Patients With Glaucoma or Ocular Hypertension." This randomized, double-blind, placebo-controlled trial enrolled 222 participants in the United States.